Corrigendum to “Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study” [EBioMedicine 2 (9) (2015) 1133–1144]

a Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK b Department of Urology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK c Academic Urology Group, University of Cambridge, Cambridge, CB2 0QQ, UK d Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden e Department of Oncology–Pathology, Karolinska Institutet, Stockholm, Sweden f Nuffield Department of Surgical Sciences, University of Oxford, Roosevelt Drive, Oxford, UK g Molecular Diagnostics and Therapeutics Group, University College London, WC1E 6BT, UK h University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK i Department of Pathology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK j Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, N-0318 Oslo, Norway k Department of Molecular Oncology, Institute of Cancer Research, Oslo University Hospitals, N-0424 Oslo, Norway l Prostate Cancer UK/Movember Centre of Excellence for Prostate Cancer Research, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK